J Korean Med Sci.  2023 Feb;38(5):e43. 10.3346/jkms.2023.38.e43.

Impact of COVID-19 Pandemic on Tuberculosis Preventive Services and Their Post-Pandemic Recovery Strategies: A Rapid Review of Literature

• Jeong Y
• Min J

• KMID: 2539200
• DOI: http://doi.org/10.3346/jkms.2023.38.e43

Abstract

Background
Coronavirus disease 2019 (COVID-19) pandemic has disrupted tuberculosis (TB) care and prevention around the world. The aim of this study is to review literature on the impact of COVID-19 on TB preventive services and discuss their policy options during and after the pandemic.
Methods
We conducted a rapid review of scientific literature on the impact of COVID-19 on TB preventive services and their recovery strategies. After conducting a line-by-line open coding, their codes were applied in the descriptive theme building process, which was guided by the End TB strategy. TB preventive measures were selected and classified into five analytical categories: 1) vaccination against TB, 2) detection and treatment of latent TB infection (LTBI), 3) screening and diagnostics, 4) active case finding and contact tracing, and 5) surveillance.
Results
We identified 93 articles, of which 65 were research articles. During the pandemic, we observed decrease in Bacillus Calmette-Guérin (BCG) coverage, TB diagnostic services, case finding activities, and LTBI management. TB case detection was declined, which was not resumed to the pre-pandemic level after loosening the lock-down. Several recommendations were highlighted: 1) secure BCG stocks and its supply chains, 2) consider catch-up activities of routine immunization and LTBI screening, 3) maintain minimal TB health services, infection prevention and control, and surveillance, 4) leverage laboratory capacity and contact tracing mechanisms, 5) consider simultaneous testing for TB and COVID-19, and 6) Incorporate digital health technologies.
Conclusions
Our findings and lessons learnt from the pandemic can aid in the development of future national TB control program.

Keyword

SARS-CoV-2; Latent Tuberculosis; Health Policy; Prevention and Control; Immunization; Screening; Surveillance

Figure

• 

  Fig. 1 Article selection process for a rapid review on impact of the COVID-19 pandemic on tuberculosis prevention services.COVID-19 = coronavirus disease 2019, TB = tuberculosis.

• 

  Fig. 2 Tuberculosis prevention thematic framework, which was applied in the knowledge synthesis, and their final analytical categories and codes.Dashed lines indicate selecting preventive measures from each pillar of the WHO End TB Strategy. Dotted lines indicate linking similar characteristics of preventive measures. Solid lines indicate merging codes into categories and themes.WHO = World Health Organization, TB = tuberculosis, UHC = universal health coverage, LTBI = latent tuberculosis infection, BCG = Bacille Calmette-Guérin.

Reference

1. COVID-19 Excess Mortality Collaborators. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21. Lancet. 2022; 399(10334):1513–1536. PMID: 35279232.

2. World Health Organization. Global Tuberculosis Report 2021. Geneva, Switzerland: World Health Organization;2021.

3. Houben RM, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med. 2016; 13(10):e1002152. PMID: 27780211.

4. World Health Organization. Implementing the End TB Strategy: The Essentials. Geneva, Switzerland: World Health Organization;2015.

5. Pai M, Kasaeva T, Swaminathan S. Covid-19's Devastating Effect on Tuberculosis Care - A Path to Recovery. N Engl J Med. 2022; 386(16):1490–1493. PMID: 34986295.

6. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMID: 33782057.

7. Booth A. Clear and present questions: formulating questions for evidence based practice. Libr Hi Tech. 2006; 24(3):355–368.

8. McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol. 2016; 75:40–46. PMID: 27005575.

9. WHO/UNICEF Joint Reporting Form on Immunization. Bacillus Calmette–Guérin (BCG) vaccination coverage. Updated 2022. Accessed July 13, 2022. https://immunizationdata.who.int/pages/coverage/BCG.html?CODE=Global&YEAR= .

10. Maltezou HC, Medic S, Cassimos DC, Effraimidou E, Poland GA. Decreasing routine vaccination rates in children in the COVID-19 era. Vaccine. 2022; 40(18):2525–2527. PMID: 35341648.

11. Chandir S, Siddiqi DA, Mehmood M, Setayesh H, Siddique M, Mirza A, et al. Impact of COVID-19 pandemic response on uptake of routine immunizations in Sindh, Pakistan: an analysis of provincial electronic immunization registry data. Vaccine. 2020; 38(45):7146–7155. PMID: 32943265.

12. McQuaid CF, Vassall A, Cohen T, Fiekert K, White RG. COVID/TB Modelling Working Group. The impact of COVID-19 on TB: a review of the data. Int J Tuberc Lung Dis. 2021; 25(6):436–446. PMID: 34049605.

13. Barcat JA, Kantor IN, Ritacco V. One hundred years of BCG vaccine. Medicina (B Aires). 2021; 81(6):1007–1014. PMID: 34875601.

14. Golandaj JA. Pediatric TB detection in the era of COVID-19. Indian J Tuberc. 2022; 69(1):104–108. PMID: 35074141.

15. Shaikh N, Pelzer PT, Thysen SM, Roy P, Harris RC, White RG. Impact of COVID-19 disruptions on global BCG coverage and paediatric TB mortality: a modelling study. Vaccines (Basel). 2021; 9(11):1228. PMID: 34835161.

16. Senoo Y, Suzuki Y, Takahashi K, Tsuda K, Tanimoto T. Prioritizing infants in a time of Bacille Calmette-Guérin vaccine shortage caused by premature expectations against COVID-19. QJM. 2020; 113(10):773–774. PMID: 32442278.

17. Namkoong H, Horita N, Ebina-Shibuya R. Concern over a COVID-19-related BCG shortage. Int J Tuberc Lung Dis. 2020; 24(6):642–643. PMID: 32552997.

18. Dockrell HM, McShane H. Tuberculosis vaccines in the era of Covid-19 - what is taking us so long? EBioMedicine. 2022; 79:103993. PMID: 35427852.

19. Rangaka MX, Hamada Y, Abubakar I. Ending the tuberculosis syndemic: is COVID-19 the (in)convenient scapegoat for poor progress? Lancet Respir Med. 2022; 10(6):529–531. PMID: 35338839.

20. Loh FK, Thong PM, Ong CW. The crucial need for tuberculosis translational research in the time of COVID-19. Lancet Respir Med. 2022; 10(6):531–533. PMID: 35338842.

21. Migliori GB, Thong PM, Akkerman O, Alffenaar JW, Álvarez-Navascués F, Assao-Neino MM, et al. Worldwide effects of coronavirus disease pandemic on tuberculosis services, January-April 2020. Emerg Infect Dis. 2020; 26(11):2709–2712. PMID: 32917293.

22. Migliori GB, Thong PM, Alffenaar JW, Denholm J, Tadolini M, Alyaquobi F, et al. Country-specific lockdown measures in response to the COVID-19 pandemic and its impact on tuberculosis control: a global study. J Bras Pneumol. 2022; 48(2):e20220087. PMID: 35475873.

23. Bagcchi S. Dismal global tuberculosis situation due to COVID-19. Lancet Infect Dis. 2021; 21(12):1636. PMID: 34838229.

24. Yadav P, Vohra C, Gopalakrishnan M, Garg MK. Integrating health planning and primary care infrastructure for COVID-19 and tuberculosis care in India: challenges and opportunities. Int J Health Plann Manage. 2022; 37(2):632–642. PMID: 34820907.

25. Geric C, Saroufim M, Landsman D, Richard J, Benedetti A, Batt J, et al. Impact of COVID-19 on tuberculosis prevention and treatment in Canada: a multicenter analysis of 10 833 patients. J Infect Dis. 2022; 225(8):1317–1320. PMID: 34919700.

26. Rodrigues I, Aguiar A, Migliori GB, Duarte R. Impact of the COVID-19 pandemic on tuberculosis services. Pulmonology. 2022; 28(3):210–219. PMID: 35219624.

27. Godoy P, Parrón I, Barrabeig I, Caylà JA, Clotet L, Follia N, et al. Impact of the COVID-19 pandemic on contact tracing of patients with pulmonary tuberculosis. Eur J Public Health. 2022; 32(4):643–647. PMID: 35325093.

28. Gigante AR, Sousa M, Aguiar A, Pinto M, Gaio R, Duarte R. The impact of COVID-19 on the TB response: data from the field. Int J Tuberc Lung Dis. 2021; 25(9):769–771. PMID: 34802502.

29. Aznar ML, Espinosa-Pereiro J, Saborit N, Jové N, Sánchez Martinez F, Pérez-Recio S, et al. Impact of the COVID-19 pandemic on tuberculosis management in Spain. Int J Infect Dis. 2021; 108:300–305. PMID: 33930543.

30. Bhatia V, Mandal PP, Satyanarayana S, Aditama TY, Sharma M. Mitigating the impact of the COVID-19 pandemic on progress towards ending tuberculosis in the WHO South-East Asia Region. WHO South-East Asia J Public Health. 2020; 9(2):95–99. PMID: 32978339.

31. Loveday M, Cox H, Evans D, Furin J, Ndjeka N, Osman M, et al. Opportunities from a new disease for an old threat: extending COVID-19 efforts to address tuberculosis in South Africa. S Afr Med J. 2020; 110(12):1160–1167. PMID: 33403958.

32. Schiza V, Kruse M, Xiao Y, Kar S, Lovejoy K, Wrighton-Smith P, et al. Impact of the COVID-19 pandemic on TB infection testing. Int J Tuberc Lung Dis. 2022; 26(2):174–176. PMID: 35086632.

33. Dean AS, Tosas Auguet O, Glaziou P, Zignol M, Ismail N, Kasaeva T, et al. 25 years of surveillance of drug-resistant tuberculosis: achievements, challenges, and way forward. Lancet Infect Dis. 2022; 22(7):e191–e196. PMID: 35248168.

34. Togun T, Kampmann B, Stoker NG, Lipman M. Anticipating the impact of the COVID-19 pandemic on TB patients and TB control programmes. Ann Clin Microbiol Antimicrob. 2020; 19(1):21. PMID: 32446305.

35. Umubyeyi Nyaruhirira A, Scholten JN, Gidado M, Suarez PG. Coronavirus disease 2019 diagnosis in low- and middle-income countries: the big new bully disrupting TB and HIV diagnostic services. J Mol Diagn. 2022; 24(4):289–293. PMID: 35123038.

36. Velavan TP, Meyer CG, Esen M, Kremsner PG, Ntoumi F. PANDORA-ID-NET and CANTAM Consortium. COVID-19 and syndemic challenges in ‘Battling the Big Three’: HIV, TB and malaria. Int J Infect Dis. 2021; 106:29–32. PMID: 33781904.

37. Homolka S, Paulowski L, Andres S, Hillemann D, Jou R, Günther G, et al. Two pandemics, one challenge-leveraging molecular test capacity of tuberculosis laboratories for rapid COVID-19 case-finding. Emerg Infect Dis. 2020; 26(11):2549–2554. PMID: 32956612.

38. Nikolayevskyy V, Holicka Y, van Soolingen D, van der Werf MJ, Ködmön C, Surkova E, et al. Impact of the COVID-19 pandemic on tuberculosis laboratory services in Europe. Eur Respir J. 2021; 57(1):2003890. PMID: 33184119.

39. Rakotosamimanana N, Randrianirina F, Randremanana R, Raherison MS, Rasolofo V, Solofomalala GD, et al. GeneXpert for the diagnosis of COVID-19 in LMICs. Lancet Glob Health. 2020; 8(12):e1457–e1458. PMID: 33091372.

40. Kumar P, Goyal JP. Tuberculosis during Covid-19 pandemic: challenges and opportunities. Indian Pediatr. 2020; 57(11):1082.

41. Min J, Kim HW, Koo HK, Ko Y, Oh JY, Kim J, et al. Impact of COVID-19 pandemic on the national PPM tuberculosis control project in Korea: the Korean PPM monitoring database between July 2019 and June 2020. J Korean Med Sci. 2020; 35(43):e388. PMID: 33169559.

42. Chan G, Triasih R, Nababan B, du Cros P, Wilks N, Main S, et al. Adapting active case-finding for TB during the COVID-19 pandemic in Yogyakarta, Indonesia. Public Health Action. 2021; 11(2):41–49. PMID: 34159059.

43. Saini V, Garg K. Case finding strategies under National Tuberculosis Elimination Programme (NTEP). Indian J Tuberc. 2020; 67(4S):S101–S106. PMID: 33308653.

44. Fei H, Yinyin X, Hui C, Ni W, Xin D, Wei C, et al. The impact of the COVID-19 epidemic on tuberculosis control in China. Lancet Reg Health West Pac. 2020; 3:100032. PMID: 34173601.

45. Arsenault C, Gage A, Kim MK, Kapoor NR, Akweongo P, Amponsah F, et al. COVID-19 and resilience of healthcare systems in ten countries. Nat Med. 2022; 28(6):1314–1324. PMID: 35288697.

46. Arentz M, Ma J, Zheng P, Vos T, Murray CJ, Kyu HH. The impact of the COVID-19 pandemic and associated suppression measures on the burden of tuberculosis in India. BMC Infect Dis. 2022; 22(1):92. PMID: 35086472.

47. Chiang CY, Islam T, Xu C, Chinnayah T, Garfin AM, Rahevar K, et al. The impact of COVID-19 and the restoration of tuberculosis services in the Western Pacific Region. Eur Respir J. 2020; 56(4):2003054. PMID: 32978310.

48. Fatima R, Akhtar N, Yaqoob A, Harries AD, Khan MS. Building better tuberculosis control systems in a post-COVID world: learning from Pakistan during the COVID-19 pandemic. Int J Infect Dis. 2021; 113(Suppl 1):S88–S90. PMID: 33744479.

49. Liu Q, Lu P, Shen Y, Li C, Wang J, Zhu L, et al. Collateral impact of the coronavirus disease 2019 (COVID-19) pandemic on tuberculosis control in Jiangsu Province, China. Clin Infect Dis. 2021; 73(3):542–544. PMID: 32857838.

50. Adewole OO. Impact of COVID-19 on TB care: experiences of a treatment centre in Nigeria. Int J Tuberc Lung Dis. 2020; 24(9):981–982. PMID: 33156771.

51. de Souza CD, Coutinho HS, Costa MM, Magalhães MA, Carmo RF. Impact of COVID-19 on TB diagnosis in Northeastern Brazil. Int J Tuberc Lung Dis. 2020; 24(11):1220–1222. PMID: 33172534.

52. Kwak N, Hwang SS, Yim JJ. Effect of COVID-19 on tuberculosis notification, South Korea. Emerg Infect Dis. 2020; 26(10):2506–2508. PMID: 32672531.

53. Beyene NW, Sitotaw AL, Tegegn B, Bobosha K. The impact of COVID-19 on the tuberculosis control activities in Addis Ababa. Pan Afr Med J. 2021; 38:243. PMID: 34104291.

54. Komiya K, Yamasue M, Takahashi O, Hiramatsu K, Kadota JI, Kato S. The COVID-19 pandemic and the true incidence of tuberculosis in Japan. J Infect. 2020; 81(3):e24–e25.

55. Behera D. Tuberculosis, COVID-19, and the end tuberculosis strategy in India. Lung India. 2020; 37(6):467–472. PMID: 33154206.

56. Bhargava A, Shewade HD. The potential impact of the COVID-19 response related lockdown on TB incidence and mortality in India. Indian J Tuberc. 2020; 67(4S):S139–S146. PMID: 33308660.

57. Wu Z, Chen J, Xia Z, Pan Q, Yuan Z, Zhang W, et al. Impact of the COVID-19 pandemic on the detection of TB in Shanghai, China. Int J Tuberc Lung Dis. 2020; 24(10):1122–1124. PMID: 33126952.

58. Kadota JL, Reza TF, Nalugwa T, Kityamuwesi A, Nanyunja G, Kiwanuka N, et al. Impact of shelter-in-place on TB case notifications and mortality during the COVID-19 pandemic. Int J Tuberc Lung Dis. 2020; 24(11):1212–1214. PMID: 33172531.

59. Lebina L, Dube M, Hlongwane K, Brahmbatt H, Lala SG, Reubenson G, et al. Trends in paediatric tuberculosis diagnoses in two South African hospitals early in the COVID-19 pandemic. S Afr Med J. 2020; 110(12):1149–1150. PMID: 33403952.

60. Lungu PS, Kerkhoff AD, Muyoyeta M, Kasapo CC, Nyangu S, Kagujje M, et al. Interrupted time-series analysis of active case-finding for tuberculosis during the COVID-19 pandemic, Zambia. Bull World Health Organ. 2022; 100(3):205–215. PMID: 35261409.

61. Filardo TD, Feng PJ, Pratt RH, Price SF, Self JL. Tuberculosis - United States, 2021. MMWR Morb Mortal Wkly Rep. 2022; 71(12):441–446. PMID: 35324877.

62. Ullrich A, Schranz M, Rexroth U, Hamouda O, Schaade L, Diercke M, et al. Impact of the COVID-19 pandemic and associated non-pharmaceutical interventions on other notifiable infectious diseases in Germany: An analysis of national surveillance data during week 1-2016 - week 32-2020. Lancet Reg Health Eur. 2021; 6:100103. PMID: 34557831.

63. Hasan T, Nguyen VN, Nguyen HB, Nguyen TA, Le HT, Pham CD, et al. Retrospective cohort study of effects of the COVID-19 pandemic on tuberculosis notifications, Vietnam, 2020. Emerg Infect Dis. 2022; 28(3):684–692. PMID: 35202526.

64. Tok PS, Kamarudin NA, Jamaludin M, Ab Razak MF, Ahmad MA, Abu Bakar FA, et al. Effect of COVID-19 on tuberculosis notification in Johor Bahru, Malaysia. Infect Dis (Lond). 2022; 54(3):235–237. PMID: 34772327.

65. Lewer D, Mulchandani R, Roche A, Cosgrove C, Anderson C. Why has the incidence of tuberculosis not reduced in London during the COVID-19 pandemic? Lancet Respir Med. 2022; 10(3):231–233. PMID: 35032431.

66. Glaziou P. Predicted impact of the COVID-19 pandemic on global tuberculosis deaths in 2020. medRxiv. October. 8. 2020; DOI: 10.1101/2020.04.28.20079582.

67. McQuaid CF, McCreesh N, Read JM, Sumner T, Houben RMGJ, et al. CMMID COVID-19 Working Group. The potential impact of COVID-19-related disruption on tuberculosis burden. Eur Respir J. 2020; 56(2):2001718. PMID: 32513784.

68. Cilloni L, Fu H, Vesga JF, Dowdy D, Pretorius C, Ahmedov S, et al. The potential impact of the COVID-19 pandemic on the tuberculosis epidemic a modelling analysis. EClinicalMedicine. 2020; 28:100603. PMID: 33134905.

69. Delamou A, Ayadi AM, Sidibe S, Delvaux T, Camara BS, Sandouno SD, et al. Effect of Ebola virus disease on maternal and child health services in Guinea: a retrospective observational cohort study. Lancet Glob Health. 2017; 5(4):e448–e457. PMID: 28237252.

70. Camara BS, Delamou AM, Diro E, El Ayadi A, Béavogui AH, Sidibé S, et al. Influence of the 2014-2015 Ebola outbreak on the vaccination of children in a rural district of Guinea. Public Health Action. 2017; 7(2):161–167. PMID: 28695091.

71. Jirjees FJ, Dallal Bashi YH, Al-Obaidi HJ. COVID-19 death and BCG vaccination programs worldwide. Tuberc Respir Dis (Seoul). 2021; 84(1):13–21. PMID: 32883062.

72. Bok K, Sitar S, Graham BS, Mascola JR. Accelerated COVID-19 vaccine development: milestones, lessons, and prospects. Immunity. 2021; 54(8):1636–1651. PMID: 34348117.

73. Marx FM, Hauer B, Menzies NA, Haas W, Perumal N. Targeting screening and treatment for latent tuberculosis infection towards asylum seekers from high-incidence countries - a model-based cost-effectiveness analysis. BMC Public Health. 2021; 21(1):2172. PMID: 34836526.

74. The Global Fund. Briefing Note on Testing for Both Tuberculosis and SARS-CoV-2. Geneva, Switzerland: The Global Fund;2021.

75. World Health Organization. COVID-19: considerations for tuberculosis (TB) care. Updated 2020. Accessed July 13, 2022. https://www.who.int/docs/default-source/hq-tuberculosis/covid-19-tb-clinical-management-info-note-dec-update-2020.pdf?sfvrsn=554b68a7_0 .

76. Centers for Disease Control and Prevention. Effect of COVID-19 on tuberculosis in the U.S. Updated 2022. Accessed July 14, 2022. https://www.cdc.gov/nchhstp/newsroom/2022/effect-of-COVID-19-TB-media-statement.html .

77. World Health Organization. Impact of the COVID-19 Pandemic on TB Detection and Mortality in 2020. Geneva, Switzerland: World Health Organization;2021.

78. Stop TB Partnership. The Potential Impact of the COVID-19 Response on Tuberculosis in High-Burden Countries: A Modelling Analysis. Geneva, Switzerland: Stop TB Partnership;2020.

79. Teo AK, Ong CW, Hsu LY. COVID-19 and TB: a progression-regression conundrum. Int J Tuberc Lung Dis. 2021; 25(6):421–423. PMID: 34049602.

80. Khan FM, Kazmi Z, Hasan MM, Dos Santos Costa AC, Ahmad S, Essar MY. Resurgence of tuberculosis amid COVID-19 in Peru: associated risk factors and recommendations. Int J Health Plann Manage. 2021; 36(6):2441–2445. PMID: 34318523.

81. Chen H, Zhang K. Insight into the impact of the COVID-19 epidemic on tuberculosis burden in China. Eur Respir J. 2020; 56(3):2002710. PMID: 32703778.

82. Zamani S, Honarvar MR, Behnampour N, Sheikhy M, Sedaghat M, Ghaemi S, et al. Decline in TB incidence during the COVID-19 pandemic. Int J Tuberc Lung Dis. 2021; 25(12):1043–1044. PMID: 34886939.

83. Coronel Teixeira R, Aguirre S, Pérez Bejarano D. Thinking about tuberculosis in times of COVID-19. J Intern Med. 2021; 289(4):589–590. PMID: 33078450.

84. Fukunaga R, Glaziou P, Harris JB, Date A, Floyd K, Kasaeva T. Epidemiology of tuberculosis and progress toward meeting global targets - worldwide, 2019. MMWR Morb Mortal Wkly Rep. 2021; 70(12):427–430. PMID: 33764960.

85. Maia CMF, Martelli DRB, Silveira DMMLD, Oliveira EA, Martelli Júnior H. Tuberculosis in Brazil: the impact of the COVID-19 pandemic. J Bras Pneumol. 2022; 48(2):e20220082. PMID: 35475872.

86. Ortiz-Martínez Y, Rodríguez-Morales AJ, Henao-Martínez AF. Decreased notification of TB cases during the COVID-19 pandemic. Int J Tuberc Lung Dis. 2022; 26(2):177–178. PMID: 35086633.

87. Cardenas-Escalante J, Fernandez-Saucedo J, Cubas WS. Impact of the COVID-19 pandemic on tuberculosis in Peru: are we forgetting anyone? Enferm Infecc Microbiol Clin. 2022; 40(1):46–47. PMID: 34456408.

88. Choi H, Ko Y, Lee CY, Chung SJ, Kim HI, Kim JH, et al. Impact of COVID-19 on TB epidemiology in South Korea. Int J Tuberc Lung Dis. 2021; 25(10):854–860. PMID: 34615583.

89. Dadras O, Alinaghi SA, Karimi A, MohsseniPour M, Barzegary A, Vahedi F, et al. Effects of COVID-19 prevention procedures on other common infections: a systematic review. Eur J Med Res. 2021; 26(1):67. PMID: 34217366.